Patents by Inventor Michael Strupp

Michael Strupp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACETYL-LEUCINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION
    Publication number: 20230346732
    Abstract: The present disclosure is directed to acetyl-leucine or a pharmaceutically acceptable salt thereof for use in improving cognitive function, mobility, or cognitive function and mobility in a subject, for example, in an elderly subject.
    Type: Application
    Filed: July 10, 2023
    Publication date: November 2, 2023
    Inventors: Mallory FACTOR, Michael STRUPP
  • BETAHISTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND A MONOAMINE OXIDASE INHIBITOR, FOR USE IN THE TREATMENT OR PREVENTION OF ONE OR MORE SYMPTOMS OF VERTIGO IN A SUBJECT
    Publication number: 20230285373
    Abstract: A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.
    Type: Application
    Filed: May 19, 2023
    Publication date: September 14, 2023
    Inventor: Michael STRUPP
  • THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES
    Publication number: 20230210799
    Abstract: The present disclosure provides for treating neurodegenerative diseases comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 15, 2023
    Publication date: July 6, 2023
    Inventor: Michael STRUPP
  • Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
    Patent number: 11690830
    Abstract: A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: July 4, 2023
    Assignee: IntraBio Ltd.
    Inventor: Michael Strupp
  • THE COMBINATION OF ACETYL LEUCINE AND 4-AMINOPYRIDINE OR ACETAZOLAMIDE FOR TREATING ATAXIA
    Publication number: 20230201150
    Abstract: The present disclosure provides methods of treating ataxia in a subject in need thereof by administering a combination of acetyl-leucine and 4-aminopyridine or a combination of acetyl-leucine and acetazolamide to the subject.
    Type: Application
    Filed: May 20, 2021
    Publication date: June 29, 2023
    Applicant: IntraBio Ltd.
    Inventor: Michael STRUPP
  • Therapeutic agents for treating restless leg syndrome
    Patent number: 11660279
    Abstract: The present disclosure provides for treatments of restless legs syndrome (RLS) or one or more symptoms associated with RLS comprising administering leucine, acetyl-leucine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: May 30, 2023
    Assignee: INTRABIO LIMITED
    Inventors: Mallory Factor, Michael Strupp
  • TREATMENT OF LATE-ONSET NEURODEGENERATIVE DISEASES IN HETEROZYGOUS NPC1 GENE MUTATION CARRIERS
    Publication number: 20230051742
    Abstract: The present disclosure provides methods of treating, preventing, or delaying the onset of a late-onset neurodegenerative disease, e.g., Niemann-Pick type C, or a symptom thereof in a subject in need thereof, comprising administering a therapeutically effective amount of acetyl-leucine to the subject, wherein the subject is heterozygous NPC1 gene mutation carrier.
    Type: Application
    Filed: January 13, 2021
    Publication date: February 16, 2023
    Applicant: IntraBio Ltd.
    Inventor: Michael STRUPP
  • COMBINATION THERAPY WITH ACETYL-LEUCINE AND MIGLUSTAT
    Publication number: 20220362189
    Abstract: The present disclosure provides methods of treating lysosomal storage disorders (LSDs) in a subject in need thereof by administering a combination of acetyl-leucine and miglustat to the subject, wherein subject is naive to treatment with miglustat.
    Type: Application
    Filed: June 26, 2020
    Publication date: November 17, 2022
    Inventors: MALLORY FACTOR, MICHAEL STRUPP
  • PHARMACEUTICAL COMPOSITIONS AND USES DIRECTED TO LYSOSOMAL STORAGE DISORDERS
    Publication number: 20220331278
    Abstract: The present disclosure provides for treating lysosomal storage disorders (LSDs) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 30, 2022
    Publication date: October 20, 2022
    Inventor: Michael STRUPP
  • Treatment for migraine
    Patent number: 11471434
    Abstract: A first aspect of the invention relates to leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a migraine, or one or more symptoms associated therewith. A second aspect of the invention relates to a method of treating or preventing a migraine, or one or more symptoms associated therewith, in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: October 18, 2022
    Assignee: INTRABIO LTD.
    Inventors: Michael Strupp, Mallory Factor
  • Pharmaceutical compositions and uses directed to lysosomal storage disorders
    Patent number: 11400067
    Abstract: The present disclosure provides for treating lysosomal storage disorders (LSDs) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: August 2, 2022
    Assignee: INTRABIO LIMITED
    Inventor: Michael Strupp
  • BETAHISTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND A MONOAMINE OXIDASE INHIBITOR, FOR USE IN THE TREATMENT OR PREVENTION OF ONE OR MORE SYMPTOMS OF VERTIGO IN A SUBJECT
    Publication number: 20210361632
    Abstract: A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.
    Type: Application
    Filed: August 6, 2021
    Publication date: November 25, 2021
    Inventor: Michael Strupp
  • Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
    Patent number: 11083718
    Abstract: A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: August 10, 2021
    Assignee: IntraBio Ltd.
    Inventor: Michael Strupp
  • ACETYL-LEUCINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION
    Publication number: 20210106548
    Abstract: The present disclosure is directed to acetyl-leucine or a pharmaceutically acceptable salt thereof for use in improving cognitive function, mobility, or cognitive function and mobility in a subject, for example, in an elderly subject.
    Type: Application
    Filed: December 22, 2020
    Publication date: April 15, 2021
    Inventors: Mallory FACTOR, Michael STRUPP
  • BETAHISTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND A MONOAMINE OXIDASE INHIBITOR, FOR USE IN THE TREATMENT OR PREVENTION OF ONE OR MORE SYMPTOMS OF VERTIGO IN A SUBJECT
    Publication number: 20210085659
    Abstract: A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.
    Type: Application
    Filed: March 28, 2018
    Publication date: March 25, 2021
    Applicant: INTRABIO LTD
    Inventor: Michael STRUPP
  • THERAPEUTIC AGENTS FOR TREATING RESTLESS LEG SYNDROME
    Publication number: 20210046031
    Abstract: The present disclosure provides for treatments of restless legs syndrome (RLS) or one or more symptoms associated with RLS comprising administering leucine, acetyl-leucine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 14, 2019
    Publication date: February 18, 2021
    Inventors: Mallory FACTOR, Michael STRUPP
  • Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
    Patent number: 10905670
    Abstract: The present disclosure is directed to acetyl-leucine or a pharmaceutically acceptable salt thereof for use in improving cognitive function, mobility, or cognitive function and mobility in a subject, for example, in an elderly subject.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: February 2, 2021
    Assignee: INTRABIO LTD.
    Inventors: Mallory Factor, Michael Strupp
  • TREATMENT FOR MIGRAINE
    Publication number: 20200253905
    Abstract: A first aspect of the invention relates to leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a migraine, or one or more symptoms associated therewith. A second aspect of the invention relates to a method of treating or preventing a migraine, or one or more symptoms associated therewith, in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 25, 2018
    Publication date: August 13, 2020
    Inventors: MICHAEL STRUPP, Mallory FACTOR
  • THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES
    Publication number: 20200179320
    Abstract: The present disclosure provides for treating neurodegenerative diseases comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 11, 2017
    Publication date: June 11, 2020
    Inventor: Michael STRUPP
  • PHARMACEUTICAL COMPOSITIONS AND USES DIRECTED TO LYSOSOMAL STORAGE DISORDERS
    Publication number: 20190201359
    Abstract: The present disclosure provides for treating lysosomal storage disorders (LSDs) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 11, 2017
    Publication date: July 4, 2019
    Inventor: Michael STRUPP